|
US2019314351A1
|
|
Pirfenidone treatment for patients with atypical liver function
|
|
US2019298704A1
|
|
Methods of Administering Pirfenidone Therapy
|
|
EP3142680A2
|
|
Lpa-associated protein and rna expression
|
|
US2017121345A1
|
|
Anti-fibrotic pyridinones
|
|
US2015111899A1
|
|
Pirfenidone therapy and inducers of cytochrome p450
|
|
AU2014240300A1
|
|
Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
|
|
KR20150130408A
|
|
Proteomic ipf markers
|
|
EP2968292A1
|
|
Methods of improving microvascular integrity
|
|
TW201437200A
|
|
Lysophosphatidic acid receptor antagonists
|
|
AR092742A1
|
|
ANTIFIBROTIC PYRIDINONES
|
|
CA2819967A1
|
|
Use of pirfenidone concomitantly with ciprofloxacin
|
|
AU2013204032A1
|
|
Method of Administering Pirfenidone Therapy
|
|
AU2013202991A1
|
|
Pirfenidone Therapy and Inducers of Cytochrome P450
|
|
AU2013201986A1
|
|
Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
|
|
US2014094456A1
|
|
Anti-fibrotic pyridinones
|
|
US2014200215A1
|
|
Lysophosphatidic acid receptor antagonists
|
|
MX2014006130A
|
|
Methods of diagnosing and treating idiopathic pulmonary fibrosis.
|
|
AU2012216834A1
|
|
Pyridone Derivatives for Modulating Stress-Activated Protein Kinase System
|
|
MX2014001732A
|
|
Lysophosphatidic acid receptor antagonists.
|
|
AU2012205256A1
|
|
Pirfenidone Treatment for Patients with Atypical Liver Function
|
